← Back to Screener
Creative Medical Technology Holdings, Inc. Common Stock (CELZ)
Price$2.06
Value ScoreD
Growth ScoreF
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-31.35%
Price vs S&P 500 (4W)-10.81%
VGM Score32.39
Market Capitalization$7.62M
All Metrics
Book Value / Share (Quarterly)$1.65
P/TBV (Annual)0.71x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-59.45%
Cash Flow / Share (Quarterly)$-1.51
Price vs S&P 500 (YTD)-3.06%
Gross Margin (TTM)63.50%
Net Profit Margin (TTM)-58762.83%
EPS (TTM)$-2.04
10-Day Avg Trading Volume0.06M
EPS Excl Extra (TTM)$-2.04
Revenue Growth (5Y)-48.14%
EPS (Annual)$-2.52
ROI (Annual)-79.78%
Gross Margin (Annual)63.50%
Net Profit Margin (5Y Avg)-39703.89%
Cash / Share (Quarterly)$1.58
Revenue Growth QoQ (YoY)0.00%
ROA (Last FY)-76.77%
Revenue Growth TTM (YoY)-78.57%
EBITD / Share (TTM)$-2.02
ROE (5Y Avg)-18.70%
Operating Margin (TTM)-60104.33%
Cash Flow / Share (Annual)$-1.58
P/B Ratio1.25x
P/B Ratio (Quarterly)1.25x
Net Income / Employee (Annual)$-1,498,800
EV / Revenue (TTM)315.33x
Net Interest Coverage (TTM)-0.03x
ROA (TTM)-84.71%
EPS Incl Extra (Annual)$-2.52
Current Ratio (Annual)25.97x
Quick Ratio (Quarterly)19.35x
3-Month Avg Trading Volume0.05M
52-Week Price Return-8.45%
Revenue / Employee (TTM)$800
Tangible BV / Share (Quarterly)$1.55
P/S Ratio (Annual)1269.19x
Asset Turnover (Annual)0.00x
52-Week High$6.25
Operating Margin (5Y Avg)-46248.59%
EPS Excl Extra (Annual)$-2.52
26-Week Price Return-23.42%
Quick Ratio (Annual)25.49x
13-Week Price Return11.35%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)19.69x
Enterprise Value$1.89M
Revenue / Share Growth (5Y)-75.20%
Asset Turnover (TTM)0.00x
Revenue / Employee (Annual)$1,500
Inventory Turnover (Annual)2.00x
Pretax Margin (Annual)-99916.83%
Cash / Share (Annual)$1.95
3-Month Return Std Dev49.26%
Gross Margin (5Y Avg)58.92%
Net Income / Employee (TTM)$-1,440,500
ROE (Last FY)-79.78%
Net Interest Coverage (Annual)-0.35x
EPS Basic Excl Extra (Annual)$-2.52
Receivables Turnover (TTM)34.00x
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-2.04
Receivables Turnover (Annual)32.00x
ROI (TTM)-88.50%
P/S Ratio (TTM)1269.19x
Pretax Margin (5Y Avg)-39703.89%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$1.92
Price vs S&P 500 (52W)-32.81%
Year-to-Date Return5.10%
5-Day Price Return-8.44%
EPS Normalized (Annual)$-2.52
ROA (5Y Avg)-18.17%
Net Profit Margin (Annual)-99916.83%
Month-to-Date Return-8.44%
Cash Flow / Share (TTM)$-6.88
EBITD / Share (Annual)$-2.53
Operating Margin (Annual)-102380.17%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-18.70%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-2.04
P/TBV (Quarterly)1.33x
P/B Ratio (Annual)0.67x
Inventory Turnover (TTM)2.00x
Pretax Margin (TTM)-58762.83%
Book Value / Share (Annual)$2.03
Price vs S&P 500 (13W)3.10%
Beta1.86x
Revenue / Share (TTM)$0.00
ROE (TTM)-88.50%
52-Week Low$1.50
vGradeD
gGradeF
mGradeC
vgmGradeD
Show chart for
Earnings Surprise History
Q1 26-0.38est. -0.40
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.14
4.14
4.14
4.14
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
CELZCreative Medical Technology Holdings, Inc. Common Stock | D | F | C | $2.06 |
| AMGNAmgen Inc | C | C | C | $349.58 |
| GILDGilead Sciences Inc | C | B | C | $129.16 |
| ARGXargenx SE American Depositary Shares | D | A | B | $891.32 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $149.23 |
| BIIBBiogen Inc. Common Stock | B | D | B | $195.34 |
| BNTXBioNTech SE American Depositary Share | C | C | D | $88.08 |
| MRNAModerna, Inc. Common Stock | C | B | B | $47.44 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $163.88 |
| EXELExelixis Inc | C | B | B | $52.70 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | A | $301.00 |
About
Creative Medical Technology Holdings Inc is a biotechnology company developing therapeutic applications of amniotic fluid-derived stem cells for regenerative medicine. The company targets reproductive and sexual health disorders, including male and female sexual dysfunction, infertility, and miscarriage-related conditions. Its business model centers on creating and licensing intellectual property in this specialized stem cell therapy space.